<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3902">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04615936</url>
  </required_header>
  <id_info>
    <org_study_id>NasalPDF001</org_study_id>
    <nct_id>NCT04615936</nct_id>
  </id_info>
  <brief_title>Nasal Photodisinfection COVID Proof of Concept Study</brief_title>
  <official_title>Methylene Blue-mediated Photodisinfection for SARS-CoV-2 in the Upper Respiratory Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study proposes to test photodisinfection (PDF) on SARS-CoV-2 in the nose. The study will&#xD;
      use Health Canada approved Steriwave™ Nasal Decolonization (ND) in he nostril of patients&#xD;
      infected with SARS-CoV-2. Participants are swabbed for SARS-CoV-2 before and after the PDF&#xD;
      treatment. For the study, a small group of healthcare workers who have tested positive for&#xD;
      SARS-CoV-2 will be included. They will not undergo the treatment but will need to swab their&#xD;
      noses multiple times over the next 5 days. This nil group will provide the effect (if any) of&#xD;
      swabbing SARS-CoV-2 levels in the nose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study proposes to test photodisinfetion (PDF) on levels of SARS-CoV-2 in the nose. The&#xD;
      study will use Health Canada approved Steriwave™ Nasal Decolonization (ND) in patients&#xD;
      infected with SARS-CoV-2 . Currrently, PDF is being used at some institutions before surgery&#xD;
      to lower the risk of postoperative infection. PDF uses a Methylene Blue (MB) nasal spray,&#xD;
      followed by 5 minutes of red-light exposure through a small light-diffusing applicator. This&#xD;
      will need to be placed into each nostril. Participants are swabbed for SARS-CoV-2 before and&#xD;
      after treatment. In addition to the patients testing positive for SARS-CoV-2, there will also&#xD;
      be a small group of healthcare workers who have tested positive that will be included. Though&#xD;
      they are not undergoing treatment, they will swab their own noses multiple times over a&#xD;
      period of 5 days. This will allow us to evaluate the effect (if any) of swabbing on&#xD;
      SARS-CoV-2 levels in the nose. The study hypothesis is that MB-mediated PDF will show the&#xD;
      ability to kill SARS-CoV-2 which will consequently confirm its efficacy as a first line&#xD;
      defense against the virus.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>There is only a single group of patients in the study who will undergo treatment. There is a small sub group/'nil' group of 3 healthcare workers that will not be undergoing the treatment but will instead be doing multiple nasal swabbing in the course of 5 days.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>N/A- masking not required</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>RT-qPCR</measure>
    <time_frame>30 minutes</time_frame>
    <description>The main endpoint is microbiological; RT-qPCR will be conducted on the pre and post treatment swabs and the change in cycle threshold value will be measured</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <condition>Corona Virus Infection</condition>
  <condition>SARS-CoV 2</condition>
  <arm_group>
    <arm_group_label>Methylene Blue-Photodisinfection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Health-Canada approved Steriwave system (Ondine Biomedical, BC) will be used to deliver the Methylene Blue-Photodisinfection (MB-PDF) to the anterior nares.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Methylene-Blue Photodisinfection</intervention_name>
    <description>Participants will receive a pre-treatment nasal swab followed MB-PDF, this involves an MB nasal spray, followed by five minutes of red-light exposure into each nostril. Ten minutes after the treatment, a post treatment nasal swab will be performed.</description>
    <arm_group_label>Methylene Blue-Photodisinfection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (patient population):&#xD;
&#xD;
          -  Recent SARS-CoV-2+ diagnosis&#xD;
&#xD;
          -  Present in hospital&#xD;
&#xD;
        Inclusion Criteria (healthcare workers):&#xD;
&#xD;
          -  Recent SARS-CoV-2+ diagnosis&#xD;
&#xD;
          -  Ability to self-administer nasal swabs&#xD;
&#xD;
        Exclusion Criteria (patient population):&#xD;
&#xD;
          -  Immediate requirement for intubation (i.e. emergency airway) or inability to maintain&#xD;
             independent oral airway&#xD;
&#xD;
        Exclusion Criteria (healthcare workers):&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cari Whyne, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cari Whyne, PhD</last_name>
    <phone>4164806100</phone>
    <phone_ext>5056</phone_ext>
    <email>cwhyne@sri.utoronto.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeremie Larouche, MD, MSc</last_name>
    <phone>4164806775</phone>
    <email>jeremie.larouche@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cari Whyne, PhD</last_name>
      <phone>4164806100</phone>
      <phone_ext>5056</phone_ext>
      <email>cwhyne@sri.utoronto.ca</email>
    </contact>
    <contact_backup>
      <last_name>Ravi Tuazon, BSc</last_name>
      <phone>4164804285</phone>
      <email>ravi.tuazon@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Cari Whyne, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>coronavirus</keyword>
  <keyword>influenza</keyword>
  <keyword>photodisinfection</keyword>
  <keyword>nasal photodisinfection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

